Oriental Insight | Professor Juliang Zhang: Insights into Adjuvant Intensified Therapy for HR+/HER2- Breast Cancer

Oriental Insight | Professor Juliang Zhang: Insights into Adjuvant Intensified Therapy for HR+/HER2- Breast Cancer

2025.10.21
Hormone receptor–positive, HER2-negative (HR+/HER2−) breast cancer is the most common molecular subtype of breast cancer. Although patients with this subtype generally have a favorable prognosis, its high heterogeneity means that some individuals remain at risk of disease recurrence.In recent years, adjuvant treatment strategies have been continuously refined — evolving from standard endocrine therapy to the incorporation of CDK4/6 inhibitors — significantly improving patient outcomes.In this edition of Oncology Frontier, Professor Juliang Zhang from the Department of Breast, Thyroid, and Vascular Surgery, Xijing Hospital, Air Force Medical University, shares his insights on adjuvant intensified therapy for HR+/HER2− breast cancer.
Oriental Insight | Professors Xiaoyun Mao and Wen Xu’s Team Publishes a Comprehensive Review on Engineered Upconversion Nanoparticles for Precision Theranostics in Breast Cancer 

Oriental Insight | Professors Xiaoyun Mao and Wen Xu’s Team Publishes a Comprehensive Review on Engineered Upconversion Nanoparticles for Precision Theranostics in Breast Cancer 

2025.10.21
Breast cancer remains the most common malignancy among women, with persistently high incidence and mortality rates. Its heterogeneity, drug resistance, and the toxicity associated with conventional therapies continue to challenge clinical management.In recent years, rare-earth-doped upconversion nanoparticles (UCNPs) have attracted growing attention in breast cancer research owing to their unique optical properties, tunable synthesis, and flexible functionalization strategies.Recently, the research teams led by Professor Xiaoyun Mao from the First Affiliated Hospital of China Medical University and Professor Wen Xu from the School of Physics and Materials Engineering, Dalian Minzu University, published a cover review in Theranostics titled 'Engineered Upconversion Nanoparticles for Breast Cancer Theranostics.'This review systematically summarizes the progress of UCNP-based strategies in breast cancer diagnosis and therapy, while also discussing challenges in clinical translation and future development directions.